Does Rallies show Form 4 insider transactions for ANVS?

Yes. Rallies tracks ANVS insider trading and Form 4 activity, including executive purchases, executive sales, transaction dates, shares, and prices when available.

Is ANVS research on Rallies investment advice?

No. Rallies provides research, data, and educational context for ANVS. It does not provide personalized investment advice.

ANVS (Annovis Bio, Inc.) Stock Analysis - Insider Trades

Annovis Bio, Inc. (ANVS) is a publicly traded Healthcare sector company. As of May 20, 2026, ANVS trades at $1.59 with a market cap of $71.03M and a P/E ratio of -1.41. ANVS moved -5.85% today. Year to date, ANVS is -46.85%; over the trailing twelve months it is -8.49%. Its 52-week range spans $1.11 to $10.54. Analyst consensus is buy with an average price target of $12.50. Rallies surfaces ANVS's financials, insider trades, hedge fund holdings, congressional trades, analyst ratings, and AI-generated research below.

Who is trading ANVS stock inside the company?

Recent ANVS insider activity includes Hoffman Michael B bought 713.80K, Hoffman Michael B bought 30.00K, Hoffman Michael B bought 15.00K, Hoffman Michael B bought 1.49K, and Hoffman Michael B bought 9.20K. Rallies tracks insider transaction dates, shares, prices, and estimated values.

ANVS Key Metrics

Key financial metrics for ANVS
Metric	Value
Price	$1.59
Market Cap	$71.03M
P/E Ratio	-1.41
EPS	$-1.40
Dividend Yield	0.00%
52-Week High	$10.54
52-Week Low	$1.11
Volume	727.16K
Avg Volume	0
Revenue (TTM)	$0
Net Income	$-28.85M
Gross Margin	0.00%

Recent ANVS Insider Trades

Hoffman Michael B bought 713.80K (~$1.50M) on Apr 2, 2026.
Hoffman Michael B bought 30.00K (~$130.19K) on Dec 8, 2025.
Hoffman Michael B bought 15.00K (~$63.60K) on Dec 8, 2025.
Hoffman Michael B bought 1.49K (~$6.15K) on Nov 24, 2025.
Hoffman Michael B bought 9.20K (~$35.42K) on Nov 24, 2025.

Latest ANVS News

Annovis Bio Launches Public Offering of Stock and Warrants to Fund Phase 3 Study — May 19, 2026
Annovis Hits 85% AD Trial Enrollment, 40% PD Extension; NDA Filings Set — May 15, 2026
Annovis CEO to Present Multi-Protein Alzheimer’s Model, Phase 3 Buntanetap Data on May 13 — May 7, 2026
Annovis’s Buntanetap Shows Dose-Dependent Cognitive Gains, Biomarker Reductions; Phase 3 80% Enrolled — Apr 28, 2026
Annovis Raises $10 Million to Fund Phase 3 Alzheimer’s Trial Through Q2 2027 — Apr 10, 2026

ANVS Analyst Consensus

2 analysts cover ANVS: 0 strong buy, 2 buy, 0 hold, 0 sell, 0 strong sell. Consensus rating is buy. Average price target: $12.50.

Common questions about ANVS

Who is trading ANVS stock inside the company?: Recent ANVS insider activity includes Hoffman Michael B bought 713.80K, Hoffman Michael B bought 30.00K, Hoffman Michael B bought 15.00K, Hoffman Michael B bought 1.49K, and Hoffman Michael B bought 9.20K. Rallies tracks insider transaction dates, shares, prices, and estimated values.
Does Rallies show Form 4 insider transactions for ANVS?: Yes. Rallies tracks ANVS insider trading and Form 4 activity, including executive purchases, executive sales, transaction dates, shares, and prices when available.
Is ANVS research on Rallies investment advice?: No. Rallies provides research, data, and educational context for ANVS. It does not provide personalized investment advice.